Table 1.
Patient characteristics.
| Derivation cohort (n = 1005) | Validation cohort (n = 752) | |
|---|---|---|
| Age, median (IQR), y | 73 (66–81) | 74 (64–81) |
| Sex | ||
| Male, n (%) | 587 (58.3) | 413 (54.9) |
| Female, n (%) | 419 (41.7) | 339 (45.1) |
| Body weight, mean ± SD, kg | 59.7 ± 13.9 | 58.8 ± 12.8 |
| Types of atrial fibrillation | ||
| Paroxysmal, n (%) | 577 (57.4) | 538 (71.5) |
| Sustained, n (%) | 429 (42.6) | 214 (28.5) |
| Comorbidities | ||
| Hypertension, n (%) | 650 (64.6) | 423 (56.3) |
| Diabetes mellitus, n (%) | 226 (22.4) | 152 (20.2) |
| Dyslipidemia, n (%) | 394 (39.2) | 358 (47.6) |
| Chronic kidney disease, n (%) | 345 (34.2) | 197 (26.1) |
| Coronary artery disease, n (%) | 129 (12.8) | 132 (17.5) |
| History of disease | ||
| Cerebral infarction, n (%) | 96 (9.5) | 77 (10.2) |
| Transient ischemic attack, n (%) | 12 (1.2) | 5 (0.7) |
| Systemic thromboembolism, n (%) | 9 (0.9) | 3 (0.4) |
| The CHADS2 score (IQR) | 2 (1–3) | 1 (1–2) |
| The CHA2DS2-VASc score (IQR) | 3 (2–4) | 3 (2–4) |
| Antithrombotic medication | ||
| Antiplatelet drug, n (%) | 322 (32.0) | 246 (32.7) |
IQR: interquartile range; SD, standard deviation.